Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) is dated August 8, 2023. The report addresses a notice received from the Nasdaq Stock Market LLC regarding the Company's failure to meet specific continued listing standards.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metrics disclosed relate to stock market listing requirements:
- Bid Price: Closed below the minimum $1.00 per share requirement for 30 consecutive business days.
- Market Value of Listed Securities (MVLS): Closed below the minimum $35 million requirement for 30 consecutive business days.
Material Changes
The material change reported is the receipt of a formal deficiency notice from Nasdaq. The Company's common stock has failed to satisfy two specific listing rules:
- Rule 5550(a)(2) (Bid Price Rule): Failure to maintain a minimum bid price of $1.00.
- Rule 5550(b)(2) (MVLS Rule): Failure to maintain a minimum market value of listed securities of $35 million.
Outlook, Risks, and Contingencies
Compliance Period: The Company has been granted an initial 180-day compliance period, ending February 5, 2024, to regain compliance.
Remediation Requirements: To cure the deficiencies, the Company must achieve the following for a minimum of ten consecutive business days prior to the deadline:
- Bid price of $1.00 or more per share.
- MVLS of $35 million or more.
Future Options and Risks: If the Company fails to regain compliance by February 5, 2024, it may be eligible for an additional 180-day period, contingent on meeting other listing standards and potentially effecting a reverse stock split. Failure to comply ultimately results in delisting. The Company is currently evaluating options, but there is no assurance that compliance will be regained.
Investor Verification Checklist
- Verify the current trading price of AVTX to assess the gap from the $1.00 threshold.
- Calculate the current Market Value of Listed Securities to determine the shortfall from $35 million.
- Monitor for announcements regarding a potential reverse stock split as a remediation strategy.
- Review upcoming quarterly reports (10-Q) for cash runway and liquidity status, as this 8-K does not contain financial data.